Modulatory impact of Bifidobacterium longum subsp. longum BL21 on the gut-brain-ovary axis in polycystic ovary syndrome: insights into metabolic regulation, inflammation mitigation, and neuroprotection/Experiment 8

From BugSigDB


Needs review

Curated date: 2025/07/08

Curator: Victoria

Revision editor(s): Victoria

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Mus musculus
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Polycystic ovary syndrome Cystic disease of ovaries,hyperandrogenemia,Multicystic ovaries,multicystic ovaries,Ovarian Degeneration, Sclerocystic,Ovarian Syndrome, Polycystic,Ovarian Syndromes, Polycystic,Ovaries, Sclerocystic,Ovary Syndrome, Polycystic,Ovary, Sclerocystic,PCO - Polycystic ovaries,Pco1,PCOD - Polycystic ovarian disease,PCOS,Pcos,PCOS - Polycystic ovarian syndrome,PCOS1,Polycystic ovarian disease,polycystic ovarian disease,Polycystic ovarian syndrome,Polycystic ovaries,polycystic ovaries,Polycystic ovaries (disorder),polycystic ovary,polycystic ovary syndrome,polycystic ovary syndrome 1,Sclerocystic Ovarian Degeneration,Sclerocystic Ovaries,Sclerocystic Ovary,Sclerocystic Ovary Syndrome,Stein Leventhal Syndrome,Stein-Leventhal synd.,Stein-Leventhal Syndrome,Stein-Leventhal syndrome,Syndrome, Polycystic Ovary,Syndrome, Stein-Leventhal,Polycystic ovary syndrome
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Polycystic Ovary Syndrome (PCOS_Baseline) group
Group 1 name Corresponds to the case (exposed) group for case-control studies
Polycystic Ovary Syndrome (PCOS_End) group
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
This group consists of mice that were given dihydrotestosterone (DHT) to induce Polycystic ovary syndrome (PCOS) (after BL21 intervention).
Group 0 sample size Number of subjects in the control (unexposed) group
8
Group 1 sample size Number of subjects in the case (exposed) group
8

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Mann-Whitney (Wilcoxon)
Kruskall-Wallis
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No


Signature 1

Needs review

Curated date: 2025/07/08

Curator: Victoria

Revision editor(s): Victoria

Source: Figure 5B

Description: Violin plots illustrating differences in gut microbiota abundance at the phylum level before and after BL21 intervention at different time points. Different letters indicate statistically significant differences between groups.

Abundance in Group 1: increased abundance in Polycystic Ovary Syndrome (PCOS_End) group

NCBI Quality ControlLinks
Thermodesulfobacteriota

Revision editor(s): Victoria

Signature 2

Needs review

Curated date: 2025/07/08

Curator: Victoria

Revision editor(s): Victoria

Source: Figure 5B

Description: Violin plots illustrating differences in gut microbiota abundance at the phylum level before and after BL21 intervention at different time points. Different letters indicate statistically significant differences between groups.

Abundance in Group 1: decreased abundance in Polycystic Ovary Syndrome (PCOS_End) group

NCBI Quality ControlLinks
Campylobacterota
Bacillota

Revision editor(s): Victoria